Abstract:Objectives: To investigate the antitumor activity of a novel agonistic single chain fragment variable (scFv) antibody TR2-3 targeting death receptor 5 (DR5) combined with cisplatin in vitro and in vivo. Methods: The in vitro cytotoxic effects of TR2-3 and cisplatin, alone or in combination on human cancer cell lines COLO205 and MDA-MB-231 were evaluated using the MTT assay. The apoptosis in cancer cells was evaluated by an Annexin V-PE apoptosis detection kit and flow cytometry. The mRNA and protein levels of DR5 were analyzed by real-time PCR and Western blot, respectively. Additionally, the in vivo antitumor activity of TR2-3 combined with cisplatin was evaluated in a xenograft model. Results: The combination treatment with TR2-3 and cisplatin for 24 h on COLO205 and MDA-MB-231 cells showed significant cytotoxicity effects by MTT assay, compared with the alone treatment. Consistent with cell viability results, the cisplatin enhanced the apoptosis-inducing effects of TR2-3 in the COLO205 cells and MDAMB-231 cells by flow cytometry. In addition, treatment with cisplatin alone for 24 h resulted in significantly up-regulating the mRNA and protein levels of DR5 in both COLO205 and MDA-MB-231 cell lines by q-PCR and Western blot assay. Moreover, the cytotoxic effects of TR2-3 can be blocked by adding the soluble DR5, and the blocking rate can be greatly reduced by co-treatment with cisplatin. These results indicated that cisplatin sensitized COLO205 and MDA-MB-231 cancer cells to TR2-3-mediated apoptosis by up-regulation of DR5 expression. Furthermore, combination therapy with TR2-3 and cisplatin enhanced tumor growth inhibition compared to treatment with TR2-3 or cisplatin alone in mice bearing COLO205 xenograft tumors. Conclusions: Our findings suggest that cisplatin enhanced the antitumor activity of TR2-3 in COLO205 and MDA-MB- 231 cancer cells through up-regulation of DR5 expression. The TR2-3 combined with cisplatin may be a promising treatment for cancer therapy.

Transfection of Pdcd5 Sensitizes Colorectal Cancer Cells to Cisplatin-Induced Apoptosis in Vitro and in Vivo

Programmed cell death 5 enhance inhibitory effect of cisplatin on growth of colorectal carcinoma cells in vivo

Transfection of PDCD5 Effect on the Biological Behavior of Tumor Cells and Sensitized Gastric Cancer Cells to Cisplatin-Induced Apoptosis

PDCD5 Promotes Cisplatin-Induced Apoptosis of Glioma Cells Via Activating Mitochondrial Apoptotic Pathway

Recombinant Human PDCD5 Sensitizes Chondrosarcomas to Cisplatin Chemotherapy in Vitro and in Vivo

Recombinant Human PDCD5 Protein Enhances Chemosensitivity of Breast Cancer in Vitro and in Vivo.

Recombinant Human PDCD5 Protein Enhances Chemosensitivities of Hematologic Malignancies

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Programmed Cell Death 4 Enhances Chemosensitivity Of Ovarian Cancer Cells By Activating Death Receptor Pathway In Vitro And In Vivo

Effect of recombinant human programmed cell death 5 protein on cell apoptosis of human bladder cancer cell line BIU87 induced by cisplatin and its mechanism

Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism]

Combination of Novel DR5 Targeting Agonistic Scfv Antibody TR2-3 with Cisplatin Shows Enhanced Synergistic Antitumor Activity in Vitro and in Vivo

Transgenic human programmed cell death 5 expression in mice suppresses skin cancer development by enhancing apoptosis

Cisplatin augments apoptosis of esophageal carcinoma cells induced by agonistic anti-hDR5 antibody by DR5 and mitochondria death pathway

DAP5 ameliorates cisplatin-induced apoptosis of renal tubular cells.

PNAS-4, a Novel Pro-Apoptotic Gene, Can Potentiate Antineoplastic Effects of Cisplatin

PCDH17 Increases the Sensitivity of Colorectal Cancer to 5-Fluorouracil Treatment by Inducing Apoptosis and Autophagic Cell Death.

Integrated Global Proteomic and Phosphoproteomic Analysis of Cisplatin-Induced Apoptosis in A549 Cells

Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells.

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

Programmed Cell Death 4 Overexpression Enhances Sensitivity to Cisplatin Via the JNK/c-Jun Signaling Pathway in Bladder Cancer.